Back to Search
Start Over
Phase II trial of trimetrexate in untreated advanced gastric carcinoma. A Southwest Oncology Group study.
- Source :
-
Investigational new drugs [Invest New Drugs] 1994; Vol. 12 (2), pp. 155-7. - Publication Year :
- 1994
-
Abstract
- Twenty-three evaluable patients with advanced gastric adenocarcinoma were treated with trimetrexate at doses of 8-12 mg/m2 intravenously daily for five days, with cycles repeated every 21 days. One complete response was seen for an overall response rate of 4% (95% confidence interval 0-22%). Hematologic toxicities of grade > or = 3 were seen in 10/23 patients, and overall any grade 3 or greater toxicity was seen in 14/23 patients. Trimetrexate has minimal activity against gastric adenocarcinoma in this study, and no further investigation of this agent at this dose and schedule is recommended in this disease.
Details
- Language :
- English
- ISSN :
- 0167-6997
- Volume :
- 12
- Issue :
- 2
- Database :
- MEDLINE
- Journal :
- Investigational new drugs
- Publication Type :
- Academic Journal
- Accession number :
- 7860235
- Full Text :
- https://doi.org/10.1007/BF00874448